Skip to content

Trial Summary

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator’s choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Acronym:

DESTINY-Breast06

ACTRN/NCT /ethics:

NCT04494425

Scientific title:

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Sponsor / Cooperative group:

AstraZeneca

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase III
Age Range18 Years to 105 Years
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-07-24
Anticipated End Date2023-07-31

Participating Hospitals

HospitalGenesisCare St Andrew's
Clinical Trial CoordinatorKimberley Ruxton
EmailKimberley.Ruxton@genesiscare.com
Phone-
Principal InvestigatorDr Nicholas Murray
Recruitment StatusRecruiting